301221-63-6

Basic information

• Product Name: TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE
• CAS NO: 301221-63-6
• Molecular Formula: C12H20BrNO3
• Molecular Weight: 306.2
• Mol File: 301221-63-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE(301221-63-6)
• EPA Substance Registry System: TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE(301221-63-6)

Safety Data

• Hazardous Substances Data: 301221-63-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE is used as a building block in organic synthesis for the creation of complex organic molecules. Its unique structure and reactivity make it a key component in the assembly of diverse chemical entities.
Used in Pharmaceutical Research:
In the pharmaceutical industry, TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE serves as an important intermediate in the development of new drugs. Its potential for functionalization allows researchers to explore its use in the synthesis of biologically active compounds with therapeutic applications.
Used in Chemical Reactions for Functionalization:
The presence of bromo and oxoethyl groups in TERT-BUTYL 4-(1-BROMO-2-OXOETHYL)PIPERIDINE-1-CARBOXYLATE makes it a promising candidate for further chemical reactions aimed at functionalization. This allows for the modification of its properties to suit specific applications in various fields, including but not limited to the pharmaceutical and chemical industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 881017-93-2 tert‐butyl 4‐(1‐bromo‐2‐ethoxy‐2‐oxoethyl)piperidine‐1‐carboxylate 
• 135716-09-5 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate 
• 135716-08-4 tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 
• 142374-19-4 tert-butyl 4-(formylmethyl)piperidine-1-carboxylate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 301221-19-2 tert-butyl 4-(imidazo[1,2-a]pyridin-3-yl)piperidine-1-carboxylate 

Relevant articles and documents

6-bromo-3-(piperidine-4-yl)imidazo[1,2-a]pyridine preparation method

The invention relates to a 6-bromo-3-(piperidine-4-yl)imidazo[1,2-a]pyridine preparation method. A purpose of the present invention is mainly to solve the technical problem that no suitable industrialsynthesis method exists in the prior art. According to the technical scheme, the method comprises five steps, and comprises: generating a compound 2 from a compound 1 and Boc2O in chloroform under the action of triethylamine; adding dichloromethane, oxalyl chloride and dimethyl sulfoxide into the compound 2, and oxidizing to obtain a compound 3; carrying out a reaction on the compound 3 and a bromination reagent phenyltrimethylammonium tribromide (PTAB) in tetrahydrofuran to obtain a compound 4; carrying out a reaction on the compound 4 and 2-amino-5-bromopyridine in ethyl alcohol to obtain acompound 5; and finally obtaining a compound 6 from the compound 5 under the action of ethyl acetate hydrochloride. According to the present invention, the obtained compound can be used as the intermediate or product for synthesis of a plurality of drugs.

NOVEL INHIBITORS

The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic heteroaryl, which may independently substituted by alkyl or amino; B is selected from alkyl, heteroalkyl, alkyl-amino, aryl, heteroaryl, cycloalkyl, heterocyclyl and alkylene, wherein said groups may independently be substituted by alkyl; D is selected from aryl-amino, heteroaryl-amino, cycloalkyl-amino, heterocyclyl, heterocyclyl-amino, urea, thioamide, thiourea, sulfonamide, sulfoximine and sulfamoyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted; and E is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted. The compounds of formula (I) are inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N- terminal glutamate residues into pyroglutamic acid under liberation of water.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE

Disclosed herein are compounds and methods which may be useful as inhibitors of GPRl 19 for the treatment or prevention of diseases including cardiovascular and metabolic diseases.

THIAZOLE DERIVATIVES AS GPR 119 MODULATORS

Compounds of formula (I) or salts, hydrates, solvates or N-oxides thereof formula (I): wherein A, B, R1, R2 and R8 are as defined herein, are useful for treating or preventing diseases or conditions which are associated with GPR119 receptor signaling, such as diabetes, obesity and metabolic syndrome.

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: Effects of fused heterocycles on antiviral activity and pharmacokinetic properties

A series of 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists containing a variety of fused heterocycles at the 4-position of the piperidine side chain has been discovered, which are orally bioavailable with potent anti-HIV activity.

Pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4, R5, R6, R14and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.